ReviewBMC pharmacology & toxicology2013
A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.
Review in BMC pharmacology & toxicology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- What Do Users of Generic Medicines Think of Them? A Systematic Review of Consumers' and Patients' Perceptions of, and Experiences with, Generic Medicines.The patient · 2016Pooled it
- Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review.BMJ open · 2015Pooled it
- What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs.BMC medicine · 2015Pooled it
- Investigation of the efficacy of generic and brand-name salmeterol/fluticasone combination in the management of asthma: a randomized comparative trial.Acta bio-medica : Atenei Parmensis · 2018Trial
- Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.BMC pharmacology & toxicology · 2017Trial
- Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence.Clinical pharmacokinetics · 2017Trial
- Contrast between innovator drug- and generic drug-induced renal dysfunction on coronary angiography (CONTRAST study).Heart and vessels · 2014Trial
- Drug Brand Switching: A Regulatory Perspective.Drug safety · 2026Review
- Article
- Not so great expectations: The role of price and name information in the nocebo effect.Exploratory research in clinical and social pharmacy · 2025Article
- The effect of attribute framing on beliefs and attitudes toward branded and generic medications.Journal of behavioral medicine · 2025Article
- Intended and Unintended Impacts of '4+7' Volume-Based Drug Procurement on the Use of Drugs in China: A Natural Experimental Study.Healthcare (Basel, Switzerland) · 2025Article
- International comparison of generic competition, prices, and usage trends: South Korea and G20 countries.Frontiers in public health · 2025Article
- Medicine affordability and access in India: lessons from generic-branded price variation under the Jan Aushadhi Scheme.Frontiers in public health · 2025Observational
- Breaking barriers: how generic drugs democratize mental health.Frontiers in pharmacology · 2025Article
- Knowledge and Perception of Consumers Towards Generic Medicines in Saudi Arabia: A Prospective Cross-Sectional Survey.Patient preference and adherence · 2025Article
- Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study.Clinical and translational science · 2024Observational
- An exploration of factors influencing the selection of generic and innovator medicines in Saudi Arabia using an observational cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Generic drugs use during the COVID-19 pandemic among Lebanese patients using psychotropics: An opportunity for generic drug promotion.Journal of generic medicines · 2023Article
- Physicians' perceptions of generic drugs in China.Health policy OPEN · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generic medicines are those where patent protection has expired, and which may be produced by manufacturers other than the innovator company. Use of generic medicines has been increasing in recent years, primarily as a cost saving measure in healthcare provision. Generic medicines are typically 20 to 90% cheaper than originator equivalents. Our objective is to provide a high-level description of what generic medicines are and how they differ, at a regulatory and legislative level, from originator medicines. We describe the current and historical regulation of medicines in the world's two main pharmaceutical markets, in addition to the similarities, as well as the differences, between generics and their originator equivalents including the reasons for the cost differences seen between originator and generic medicines. Ireland is currently poised to introduce generic substitution and reference pricing. This article refers to this situation as an exemplar of a national system on the cusp of significant health policy change, and specifically details Ireland's history with usage of generic medicines and how the proposed changes could affect healthcare provision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.